Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VGOAL-J vortioxetine effectiveness on goal achievement and work productivity in MDD (Japan)
jRCT1031210200Recruiting
- Sponsor
- Lundbeck
- Start
- Jul 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Open-label, single-arm trial of vortioxetine in major depressive disorder (MDD), sponsored by Lundbeck. Primary endpoints: Goal achievement with vortioxetine in working MDD patients and Change in work productivity. Started Jul 2021; status: recruiting.
02
Drugs
vortioxetine
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on jRCT1031210200.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT1031210200.